Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | CA5A | P35218 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | CA6 | P23280 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548341 | 1.00 | LMNA (0.81) | LMNACA5APKMCA12CA1 | |
| SCHEMBL19272079 | 0.91 | LMNA (0.68) | LMNACA5APKMCA12CA1 | |
| Acetosyringone SCHEMBL15511 | 0.90 | LMNA (1.00) | LMNACA5APKMCA12CA1 | |
| SCHEMBL4545186 | 0.87 | LMNA (0.62) | LMNACA5APKMCA12CA1 | |
| SCHEMBL14516907 | 0.87 | LMNA (0.62) | LMNACA5APKMCA12CA1 | |
| SCHEMBL2338863 | 0.86 | LMNA (0.84) | LMNACA5APKMCA12CA1 | |
| SCHEMBL17655678 | 0.84 | CA12 (0.81) | LMNACA5APKMCA12CA1 | |
| SCHEMBL29393519 | 0.84 | CA12 (0.81) | LMNACA5APKMCA12CA1 | |
| SCHEMBL6944075 | 0.82 | LMNA (0.78) | LMNACA5APKMCA12CA1 | |
| SCHEMBL29278705 | 0.82 | LMNA (0.78) | LMNACA5APKMCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4205750-B1 | NADPH OXIDASE INHIBITOR FOR SUPPRESSING OR IMPROVING HAIR LOSS OR TREATING ALOPECIA | EADERM CO LTD (JP) | 2025-04-09 | — | — | EP | claimed |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | claimed |
| US-20240066021-A1 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-29 | — | — | US | claimed |
| EP-4277703-A1 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | Children's Hospital Medical Center (US) | 2023-11-22 | — | — | EP | claimed |
| WO-2022155495-A1 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-07-21 | — | — | WO | claimed |
| EP-3980400-B1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | UNIV EMORY (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | UNIV EMORY (US) | 2025-04-10 | — | — | US | disclosed |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | EMORY UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20250049839-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-02-13 | — | — | US | disclosed |
| US-20250041374-A1 | WILLOW EXTRACT AND ITS USE IN TREATING A VIRAL INFECTION, ALLERGIC REACTION, AND OTHER MEDICAL CONDITIONS | SHIREEN NATURE COMPANY FOR GENERAL TRADING LTD. (IQ) | 2025-02-06 | — | — | US | disclosed |
| US-12161663-B2 | Compositions and methods for targeting cells | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2022217155-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220323531-A1 | WILLOW EXTRACT AND ITS USE IN TREATING A VIRAL INFECTION, ALLERGIC REACTION, AND OTHER MEDICAL CONDITIONS | SHIREEN NATURE COMPANY FOR GENERAL TRADING LTD. (IQ) | 2022-10-13 | — | — | US | disclosed |
| WO-2022217153-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022217154-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022212314-A1 | WILLOW EXTRACT AND ITS USE IN TREATING CORONAVIRUS INFECTION, INFLAMMATION, AND ASSOCIATED MEDICAL CONDITIONS | SHIREEN NATURE COMPANY FOR GENERAL TRADING, LTD. (IQ) | 2022-10-06 | — | — | WO | disclosed |
| US-20220273753-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY | 2022-09-01 | — | — | US | disclosed |
| WO-2022155495-A1 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-07-21 | — | — | WO | disclosed |
| EP-3980400-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | Emory University (US) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12161663-B2 | Compositions and methods for targeting cells | CD47, CD44, CX3CR1 | LMNA 428/4885CA5A 1882/4885PKM 2157/4885 |
| US-20250049839-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLS | CD47, CD44, CX3CR1 | LMNA 428/4885CA5A 1882/4885PKM 2157/4885 |
| US-20220273753-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | ACE2, SARS1, VIP | LMNA 3171/4885CA5A 4286/4885PKM 2399/4885 |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | ACE2, SARS1, HAVCR2 | LMNA 2953/4885CA5A 4337/4885PKM 2324/4885 |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | PNP, MTAP, NOP2 | LMNA 712/4885CA5A 4002/4885PKM 1768/4885 |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | NOX1, NOX3, NOX4 | LMNA 3927/4885CA5A 1732/4885PKM 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.